If cancer were easy, every cell would do it

A new Scientific Reports paper puts an evolutionary twist on a classic question. Instead of asking why we get cancer, Leonardo Oña of Osnabrück University and Michael Lachmann of the Santa Fe Institute use signaling theory to explore how our bodies have evolved to keep us from getting more cancer.

It isn't obvious why, when any cancer arises, it doesn't very quickly learn to take advantage of the body's own signaling mechanisms for quick growth. After all, unlike an infection, cancers can easily use the body's own chemical language. "Any signal that the body uses, an infection has to evolve to make," says Lachmann. "If a thief wants to unlock your house, they have to figure out how to pick the lock on the door. But cancer cells have the keys to your house. How do you protect against that? How do you protect against an intruder who knows everything you know, and has all the tools and keys you have?" Their answer: You make the keys very costly to use.

Oña and Lachmann's evolutionary model reveals two factors in our cellular architecture that thwart cancer: the expense of manufacturing growth factors ("keys") and the range of benefits delivered to cells nearby. Individual cancer cells are kept in check when there's a high energetic cost for creating growth factors that signal cell growth. To understand the evolutionary dynamics in the model, the authors emphasize the importance of thinking about the competition between a mutant cancerous cell and surrounding cells. When a mutant cell arises and puts out a signal for growth, that signal also provides resources to adjacent, non-mutated cells. Thus, when the benefits are distributed to a radius around the signaling cell, the mutant cells have a hard time out-competing their neighbors and can't get established. The cancer loses the ability to give the signal.

The work represents a novel application of evolutionary biology toward a big-picture understanding of cancer. Oña and Lachmann draw from the late biologist Amos Zahavi's handicap principle, which explains how evolutionary systems are stabilized against "cheaters" when dishonest signals are costlier to produce than the benefit they provide. The male peacock's elaborate tail is the classic example of a costly signal - an unhealthy bird would not have the energetic resources to grow an elaborate tail, and thus could not "fake" a signal of their evolutionary fitness. By the handicap principle, a cancer cell would be analogous to the unhealthy peacock that can't afford to signal for attention.

So how do some cancer cells overcome these evolutionary constraints? The authors point out that their model only addresses the scenario of an individual cancer trying to invade a healthy population. Once a cancer has overcome the odds of extinction and reached a certain critical size, other dynamics prevail.

"Many mechanisms seem to have evolved to prevent cancer -- from immune system control, cell death, limits on cell proliferation, to tissue architecture," the authors write. "Our model only studies the reduced chance for invasion."

"Cancer is incredibly complex," Lachmann says, "and our model is relatively simple. Still, we believe it's an important step toward understanding cancer and cancer prevention in evolutionary terms."

Oña L, Lachmann M.
Signalling architectures can prevent cancer evolution.
Sci Rep 10, 674, 2020. doi: 10.1038/s41598-020-57494-w.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

Bayer and Nuvisan create new research unit in Berl…

Bayer AG today announced that it entered into a definitive agreement to transfer a large part of its Berlin-based small molecule research unit to Nuvisan, an internationa...

Novartis announces MET inhibitor capmatinib (INC28…

Novartis announced that the US Food and Drug Administration (FDA) accepted and granted Priority Review to capmatinib’s (INC280) New Drug Application (NDA). Capmatinib is ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...

Can bilingualism protect the brain even with early…

A study by York University psychology researchers provides new evidence that bilingualism can delay symptoms of dementia. Alzheimer's disease is the most common form of d...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...